2011 RD 
2012 ME 
2013 MH 
2014 OPTIC PIT 
2015 CSCR 
2016 FLOATERS 
2017 ENDOPHTHALMITIS 
http://www.evrs.eu/medias/2009/congress/Hemorrhages.flv Author: Sophie J. Bakri, Rochester, MN, USA Advantages: Surgical displacement of medium-sized thick submacular hemorrhage has the advantage of minimizing the toxic effects of blood on the retina. Methods: Pars plana vitrectomy, subretinal tPA and air-fluid exchange is performed. The patient lies flat on his back for 30 minutes, then upright for the next 24 hours. Effectiveness /...
Read MoreSurgical Displacement of Medium-Sized Submacular Hemorrhage
Posted by Sophie J. Bakri on Oct 1, 2009 in Submacular Haemorrhage
Vitrectomy Session – Silicone
Posted by Jean-Paul Berrod, Alireza Ramezani, Masoud Soheilian, Klaus Lucke, Marcio Nehemy, Jerzy Nawrocki, Hassan A. Mortada, Claude Boscher, Paolo Chelazzi, Andreas Weinberger, Frank Becquet, Sophie J. Bakri and Marco Zemella on Oct 1, 2007 in Complication - Toxicity, Silicone oil, Vitrectomy
http://www.evrs.eu/medias/2007/videos/vitrectomysession-silicone.flv
Read MoreStability of Bevacizumab (Avastin) after Withdrawal into a Syringe and Refrigeration or Freezing
Posted by Colin A. McCannel, Sophie J. Bakri, Melissa Snyder, Jose S. Pulido, Frederick J. Troendle, William T. Weiss and Ravinder Singh on Oct 1, 2006 in Bevacizumab Avastin, Experimental Study
Colin A. McCannel, MD (Rochester, MN), Sophie J. Bakri, MD (Rochester, MN), Melissa R. Snyder, PhD (Rochester, MN), Jose S. Pulido, MD (Rochester, MN), Michael W. Stewart, MD (Jacksonville, FL), Frederick J. Troendle, PhD (Jacksonville, FL), William T. Weiss, (Rochester, MN), Ravinder J. Singh, PhD (Rochester, MN) PURPOSE: To assess the stability of bevacizumab (Avastin) over time after withdrawal into a syringe and refrigeration or...
Read MorePharmacokinetics of Intravitreal Bevacizumab (Avastin)
Posted by Sophie J. Bakri, Melissa Snyder, Jose S. Pulido, Joel Reid and Ravinder Singh on Oct 1, 2006 in Bevacizumab Avastin, Experimental Study
http://www.evrs.eu/medias/2006/congress/Pharmacokinetics-of-Intravitreal-Bevacizumab-(Avastin).swf Sophie J Bakri, MD (Cleveland, OH), Melissa Snyder, PhD (Rochester, MN), Jose S. Pulido, MD (Rochester, MN), Joel Reid, PhD (Rochester, MN), Ravinder Singh, PhD (Rochester, MN) PURPOSE: To describe the pharmacokinetics of 1.25 mg of intravitreal bevacizumab (avastin). METHODS: 1.25 mg (0.05cc) of bevacizumab was injected into the vitreous...
Read MoreAbsence of Histologic Retinal Toxicity with Standard Clinical Doses of Intravitreal Bevacizumab in a Rabbit Model
Posted by Sophie J. Bakri, J. D. Cameron, Jose S. Pulido, Colin A. McCannel and Ronald Marler on Oct 1, 2006 in Bevacizumab Avastin, Complication - Toxicity, Experimental Study
Sophie J Bakri, MD (Cleveland, OH), J.D. Cameron, MD (Rochester, MN), Jose S. Pulido, MD (Rochester, MN), Colin A. McCannel, MD (Rochester, MN), Ronald Marler, DVM, PhD (Scottsdale, AZ) PURPOSE: To evaluate the retinal toxicity of intravitreal bevacizumab in an animal model. METHODS: Bevacizumab was injected into the vitreous of one eye of each of 8 Dutch-belted rabbits; the other eye served as a control. Four rabbits received a dose of...
Read More